lerdelimumab
mAbexperimental
Clinical trial activity
0 trials · 0 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0
Mechanism of action
- Transforming growth factor beta-2INHIBITOR
TGFB2 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2108967 ↗
Also known as
- 6b1 igg4 monoclonal antibody
- cat-152
- cat-152
- lerdelimumab
- lerdelimumab
- mab 6b1 igg4
- monoclonal antibody 6b1 igg4
- trabio